M.S.D. LIMITED

During a site visit to MSD Brinny MSD raised with Oireachtas members present the importance of the R&D Tax Credit to MSD's operations across the country, highlighted the challenges with the current access and reimbursement system in Ireland and discussed the importance of…

to highlight the importance of the R&D Tax Credit to MSD Ireland's manufacturing operations R&D and to highlight the potential benefits for Ireland from enhancing the R&D Tax Credit.

To discuss MSD's footprint in Ireland, to discuss the EU competitiveness and the policy and operating environment for the pharmaceutical industry in Europe.

To raise awareness of Pulmonary Arterial Hypertension in Ireland and to advocate for health policy change to better support patients with Pulmonary Arterial Hypertension in Ireland.

To highlight to the Minister for Health some of the activities MSD Ireland is undertaking to raise public awareness to help combat HPV related cancer in Ireland and to highlight how MSD Ireland is fully committed to supporting efforts to eliminate cervical cancer in Ireland in…

To highlight the importance during this reform process of ensuring; data confidentiality, restricted access to confidential data on the common data platform, R&D studies are exempt from study notification requirements and that The European Medicines Agency (EMA) remains in the…

To highlight to new office holders the importance of focusing on, Healthcare Innovation, Improving Access to Medicines, the EU Pharmaceutical Legislation Revision (GPL), Public Health Initiatives and the development of a new Life Sciences Strategy in Ireland.

to discuss with Irish European political stakeholders MSD Ireland's position on the current negotiations at the EU Council on the Reform of the EU pharmaceutical legislation (GPL) and the need to ensure that a strong regulatory Data Protection baseline of 8 years remains in…

to highlight to MEP Kelleher how dedicated new medicines funding was not spent on new medicines as anticipated between 2021 and 2023.

To call for a fairer legislative text on the UWWTD which should include other sectors in line with the EU Polluter Pays Principal. ::To request a delay in the signing off on the Directive until a thorough assessment by the legal service of the EU Council is conducted, and an…

To update political stakeholders on the importance of addressing health challenges in Ireland as they relate to access to medicines, oncology services and screening, vaccines, rare diseases and the EU pharmaceutical revision proposals through the provision of the MSD Ireland…

To discuss rare disease policy development in Ireland and to advocate for increased attention on the the rare disease health policy area in the Oireachtas.

To highlight to Irish MEPs, MSD Ireland’s key EU health policy priorities in advance of the European Elections in May 2024 including Better Health for All Europeans, Creating Jobs that Matter, Supporting Innovation and Encouraging Sustainability. ::To highlight to Irish MEPs,…

To raise industry wide concerns in Ireland regarding the impact of some aspects of the EU Commission’s proposals to revise the general pharmaceutical legislation, on IP protection.::To discuss the Irish Government's position of support, at present, for the Commissions proposals…

To highlight to the new Minister of Finance MSD Ireland’s key health policy areas including reform of the EU pharmaceutical legislation (GPL) and reform of the reimbursement system so as to prevent the current delays for patients in Ireland accessing new medicines.